132 related articles for article (PubMed ID: 18035418)
1. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency.
Yang Z; Wang L; Wang H; Shang X; Niu W; Li J; Wu Y
Mol Immunol; 2008 Mar; 45(6):1674-81. PubMed ID: 18035418
[TBL] [Abstract][Full Text] [Related]
2. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
3. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
5. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors.
Mizukami S; Kajiwara C; Ishikawa H; Katayama I; Yui K; Udono H
Cancer Sci; 2008 May; 99(5):1008-15. PubMed ID: 18341654
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
Croce M; Meazza R; Orengo AM; Fabbi M; Borghi M; Ribatti D; Nico B; Carlini B; Pistoia V; Corrias MV; Ferrini S
Cancer Immunol Immunother; 2008 Nov; 57(11):1625-34. PubMed ID: 18324400
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
8. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
9. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
10. A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells.
Chen H; Yuan B; Zheng Z; Liu Z; Wang S; Liu Y
Cell Immunol; 2011; 272(1):102-6. PubMed ID: 22032907
[TBL] [Abstract][Full Text] [Related]
11. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
[TBL] [Abstract][Full Text] [Related]
12. Tumor secreting high levels of IL-15 induces specific immunity to low immunogenic colon adenocarcinoma via CD8+ T cells.
Araki A; Hazama S; Yoshimura K; Yoshino S; Iizuka N; Oka M
Int J Mol Med; 2004 Oct; 14(4):571-6. PubMed ID: 15375583
[TBL] [Abstract][Full Text] [Related]
13. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
[TBL] [Abstract][Full Text] [Related]
14. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
[TBL] [Abstract][Full Text] [Related]
16. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
17. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine.
Monzavi-Karbassi B; Pashov A; Jousheghany F; Artaud C; Kieber-Emmons T
Int J Mol Med; 2006 Jun; 17(6):1045-52. PubMed ID: 16685414
[TBL] [Abstract][Full Text] [Related]
18. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; van der Burg SH; Offringa R
Eur J Immunol; 2008 Apr; 38(4):1033-42. PubMed ID: 18350546
[TBL] [Abstract][Full Text] [Related]
19. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
Kim TS; Lee BC; Kim E; Cho D; Cohen EP
Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
